Sientra (SIEN) Shoots Up 21% Despite Rough Market Conditions

Sientra (SIEN) shot up 21% today, despite the market sell-off. It’s unclear why SIEN had such a great day. The Company’s latest press release is from last week where the Company announced that they have received regulatory approval to market breast implants in Saudi Arabia.

Sientra offers innovative solutions and products around breast implants and are therefore housed in the PRISM Med Devices Index, which is down 1% for the day.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company’s mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at

For Canadian plastic surgeons and consumers seeking further information about Sientra silicone gel breast implants, including important safety information concerning breast implants, please visit

Share This Article


About the Author

Sientra (SIEN) Shoots Up 21% Despite Rough Market Conditions

Prism MarketView